Cambridge, United Kingdom
LoQus23 Therapeutics Ltd, founded in 2019, is a biotechnology company based in the United Kingdom that focuses on combating neurodegenerative diseases. With the slogan "Stopping DNA instability; Slowing neurodegenerative disease," LoQus23 is committed to the discovery of oral small molecule therapies. They target aberrant DNA mismatch repair, offering potential treatments for conditions like Huntington’s disease and other triplet repeat disorders.
The company secured a £7.00M Seed Round investment on 23 November 2021, an attestation to its promise and potential in addressing these critical health issues. Esteemed investors, including Novartis Venture Fund and Dementia Discovery Fund, recognize the strategic value and unique proposition loQus23 brings to the biotechnology sphere.
As LoQus23 advances, monitoring their progress in drug discovery will be crucial for investors aiming to partake in innovative solutions for challenging neurodegenerative diseases.
